m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02119)
Name
ML315
Synonyms
ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H13Cl2N3O2
InChI
1S/C18H13Cl2N3O2/c19-13-3-11(4-14(20)6-13)7-22-18-15(8-21-9-23-18)12-1-2-16-17(5-12)25-10-24-16/h1-6,8-9H,7,10H2,(H,21,22,23)
InChIKey
JQSJAVBMIMDUFO-UHFFFAOYSA-N
PubChem CID
46926514
TTD Drug ID
D0UI7U
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [2]
References
Ref 1 N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015 Feb 26;518(7540):560-4. doi: 10.1038/nature14234.
Ref 2 Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3. doi: 10.1021/ml400137s. eCollection 2013 Jun 13.